158 related articles for article (PubMed ID: 11053807)
1. Multinational cooperation in trials and guidelines dealing with febrile neutropenia.
Feld R
Int J Antimicrob Agents; 2000 Oct; 16(2):185-7. PubMed ID: 11053807
[TBL] [Abstract][Full Text] [Related]
2. Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies.
Feld R; Paesmans M; Freifeld AG; Klastersky J; Pizzo PA; Rolston KV; Rubenstein E; Talcott JA; Walsh TJ; ;
Clin Infect Dis; 2002 Dec; 35(12):1463-8. PubMed ID: 12471564
[TBL] [Abstract][Full Text] [Related]
3. Prediction of neutropenia.
Rolston KV
Int J Antimicrob Agents; 2000 Oct; 16(2):113-5. PubMed ID: 11053790
[TBL] [Abstract][Full Text] [Related]
4. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.
Uys A; Rapoport BL; Anderson R
Support Care Cancer; 2004 Aug; 12(8):555-60. PubMed ID: 15197637
[TBL] [Abstract][Full Text] [Related]
5. Proceedings of the 4th International Symposium on Febrile Neutropenia. December 15-17, 1999.
Int J Antimicrob Agents; 2000 Oct; 16(2):83-187. PubMed ID: 11203263
[No Abstract] [Full Text] [Related]
6. Italian guidelines for the management of infectious complications in pediatric oncology: empirical antimicrobial therapy of febrile neutropenia.
Viscoli C; Castagnola E; Caniggia M; De Sio L; Garaventa A; Giacchino M; Indolfi P; Izzi GC; Manzoni P; Rossi MR; Santoro N; Zanazzo GA; Masera G
Oncology; 1998; 55(5):489-500. PubMed ID: 9732231
[TBL] [Abstract][Full Text] [Related]
7. New strategies in the treatment of infectious complications in haematology and oncology: is there a role for out-patient antibiotic treatment of febrile neutropenia?
Karthaus M; Carratalà J; Jürgens H; Ganser A
Chemotherapy; 1998; 44(6):427-35. PubMed ID: 9755304
[TBL] [Abstract][Full Text] [Related]
8. Review of amikacin usage in the EORTC trials.
Zinner SH
Am J Med; 1985 Jul; 79(1A):17-20. PubMed ID: 3895903
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.
Flowers CR; Seidenfeld J; Bow EJ; Karten C; Gleason C; Hawley DK; Kuderer NM; Langston AA; Marr KA; Rolston KV; Ramsey SD
J Clin Oncol; 2013 Feb; 31(6):794-810. PubMed ID: 23319691
[TBL] [Abstract][Full Text] [Related]
10. Risk factors assessment in fabrile neutropenia.
Paesmans M
Int J Antimicrob Agents; 2000 Oct; 16(2):107-11. PubMed ID: 11053789
[TBL] [Abstract][Full Text] [Related]
11. Management of the cancer patient with infection and neutropenia.
Rapoport BL
Semin Oncol; 2011 Jun; 38(3):424-30. PubMed ID: 21600373
[TBL] [Abstract][Full Text] [Related]
12. Management of infection in cancer patients. studies of the EORTC International Antimicrobial Therapy Group (IATG).
Viscoli C;
Eur J Cancer; 2002 Mar; 38 Suppl 4():S82-7. PubMed ID: 11858971
[TBL] [Abstract][Full Text] [Related]
13. A European Organization for Research and Treatment of Cancer-International Antimicrobial Therapy Group Study of secondary infections in febrile, neutropenic patients with cancer.
Akova M; Paesmans M; Calandra T; Viscoli C;
Clin Infect Dis; 2005 Jan; 40(2):239-45. PubMed ID: 15655741
[TBL] [Abstract][Full Text] [Related]
14. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
[TBL] [Abstract][Full Text] [Related]
15. Febrile neutropenia in children.
Crokaert F
Int J Antimicrob Agents; 2000 Oct; 16(2):173-6. PubMed ID: 11053804
[TBL] [Abstract][Full Text] [Related]
16. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
Baskaran ND; Gan GG; Adeeba K
Ann Hematol; 2008 Jul; 87(7):563-9. PubMed ID: 18437382
[TBL] [Abstract][Full Text] [Related]
17. An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients.
Viscoli C; Bruzzi P; Glauser M
Eur J Cancer; 1995 Nov; 31A(12):2013-22. PubMed ID: 8562158
[TBL] [Abstract][Full Text] [Related]
18. The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia: salient features and comments.
Rolston KV
Clin Infect Dis; 2004 Jul; 39 Suppl 1():S44-8. PubMed ID: 15250020
[TBL] [Abstract][Full Text] [Related]
19. Criteria for response in patients in clinical trials of empiric antibiotic regimens for febrile neutropenia. Is there agreement?
Feld R
Support Care Cancer; 1998 Sep; 6(5):444-8. PubMed ID: 9773461
[TBL] [Abstract][Full Text] [Related]
20. [Application of the concepts of evidence-based medicine to the evidence on the treatment of febrile neutropenia].
Jarque I; Sanz MA
Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():95-102. PubMed ID: 10605194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
